ANTI-VEGF THERAPY: SETTING A NEW STANDARD FOR AMD TREATMENT

ANTI-VEGF THERAPY: SETTING A NEW STANDARD FOR AMD TREATMENT

Similar questions have been raised about the efficacy of pegaptanib in patients with predominantly classic lesions because of the subset analysis of each individual trial, which suggests that this subset of patients did not benefit in study 1003 (non-US trial). Assessing the efficacy of pegaptanib i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology Times 2005-08, Vol.30, p.3
Hauptverfasser: D'Amico, Donald J, Packo, Kirk H
Format: Artikel
Sprache:eng
Schlagworte:
Angiogenesis
Blindness
Blood vessels
Diabetic retinopathy
Disease
Drug therapy
Edema
Macular degeneration
Medical treatment
Ophthalmology
Photodynamic therapy
Pilot projects
Prescription drugs
Vascular endothelial growth factor
Visual acuity
Webcasting
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Similar questions have been raised about the efficacy of pegaptanib in patients with predominantly classic lesions because of the subset analysis of each individual trial, which suggests that this subset of patients did not benefit in study 1003 (non-US trial). Assessing the efficacy of pegaptanib in predominantly classic lesions is also complicated by the fact that PDT was allowed at the investigators' discretion in both treatment arms.
ISSN:0193-032X
2150-7333